Insider Sell: Iveric Bio
5:16PM ET 1/04/2022 MT NewswiresKeith Westby, Senior Vice President & COO, on December 31, 2021, sold 12,278 shares in Iveric Bio (ISEE) for $201,265. Following the Form 4 filing with the...
Quotes Snapshot > ISEE
Iveric Bio Inc ISEE:NASDAQ
Last Price$12.15NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$12.11 (119)
Ask (Size)$12.16 (2)
Day Low / HighN/A - N/A
Volume1.1 M
Read more news Recent News
Insider Sell: Iveric Bio
5:16PM ET 1/04/2022 MT NewswiresDavid Francis Carroll, Senior Vice President, CFO and Treasurer, on December 31, 2021, sold 15,819 shares in Iveric Bio (ISEE) for $259,310. Following the...
IVERIC bio Names Tony Gibney Chief Business and Strategy Officer
5:15PM ET 12/13/2021 MT NewswiresIVERIC bio (ISEE) said late Monday Tony Gibney has been appointed as chief business and strategy officer, effective immediately. Most recently, Gibney was...
--HC Wainwright Adjusts Price Target on Iveric Bio to $26 From $20, Keeps Buy Rating
7:17AM ET 11/10/2021 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
IVERIC (ISEE) Investor presentation - Slideshow
2:10AM ET 12/01/2021 Seeking AlphaIVERIC bio (ISEE) Investor Presentation - Slideshow
8:12AM ET 11/23/2021 Seeking AlphaIVERIC bio, Inc. 2021 Q3 - Results - Earnings Call Presentation
2:40PM ET 11/09/2021 Seeking AlphaIVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2021 Results - Earnings Call Transcript
1:49PM ET 11/09/2021 Seeking AlphaCompany Profile
Business DescriptionIVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY. View company web site for more details
| Address | Five Penn Plaza New York, New York 10001 |
| Phone | +1.212.845.8200 |
| Number of Employees | 35 |
| Recent SEC Filing | 01/11/2022 8-K |
| Chief Executive Officer & Director | Glenn P. Sblendorio |
| President | Pravin U. Dugel |
| Chief Operating Officer & Senior Vice President | Keith Westby |
| Chief Financial Officer, Treasurer & Senior VP | David F. Carroll |
Company Highlights
| Price Open | $12.48 |
| Previous Close | $12.54 |
| 52 Week Range | $4.96 - 19.32 |
| Market Capitalization | $1.4 B |
| Shares Outstanding | 114.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/02/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.12 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -59.01% |
Analyst Ratings as of 10/25/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |